TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | ---- | 102.97%3.5M | ---- | 67.04%-118.03M | ---- | -129.13%-358.06M | ---- | 351.04%1.23B | ---- | -133.80%-489.66M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | -425.57%-3.47M | ---- | 55.79%-661K | ---- | -33.60%-1.5M | ---- | 1.76%-1.12M | ---- | -554.60%-1.14M |
Interest expense - adjustment | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 75.36%112.53M |
Impairment and provisions: | ---- | -631.77%-40.28M | ---- | -95.52%7.57M | ---- | 283.97%168.95M | ---- | 126.37%44M | ---- | 153.20%19.44M |
-Impairment of property, plant and equipment (reversal) | ---- | ---- | ---- | 242.37%27.84M | ---- | -18.47%8.13M | ---- | --9.97M | ---- | ---- |
-Impairmen of inventory (reversal) | ---- | -163.71%-6.77M | ---- | 5.42%10.63M | ---- | -51.20%10.08M | ---- | 199.74%20.66M | ---- | 67.43%6.89M |
-Impairment of trade receivables (reversal) | ---- | 11.93%-22.64M | ---- | -117.05%-25.7M | ---- | 1,027.69%150.74M | ---- | 24.72%13.37M | ---- | 201.07%10.72M |
-Other impairments and provisions | ---- | -109.34%-10.87M | ---- | ---5.19M | ---- | ---- | ---- | ---- | ---- | --1.83M |
Revaluation surplus: | ---- | ---- | ---- | 422.44%52.55M | ---- | --10.06M | ---- | ---- | ---- | --630K |
-Fair value of investment properties (increase) | ---- | ---- | ---- | --52.55M | ---- | ---- | ---- | ---- | ---- | ---- |
-Other fair value changes | ---- | ---- | ---- | ---- | ---- | --10.06M | ---- | ---- | ---- | --630K |
Asset sale loss (gain): | ---- | 2,293.81%14.32M | ---- | -96.83%598K | ---- | 101.09%18.88M | ---- | -30,968.78%-1.74B | ---- | 120.33%5.63M |
-Loss (gain) from sale of subsidiary company | ---- | ---9.74M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | ---- | 4,498.66%27.5M | ---- | -96.83%598K | ---- | 145.16%18.88M | ---- | 36.92%7.7M | ---- | 80.93%5.63M |
-Loss (gain) from selling other assets | ---- | ---3.44M | ---- | ---- | ---- | ---- | ---- | ---1.74B | ---- | ---- |
Depreciation and amortization: | ---- | -26.71%74.66M | ---- | -13.21%101.87M | ---- | -10.77%117.38M | ---- | 5.40%131.55M | ---- | 20.31%124.81M |
Financial expense | ---- | -50.62%13.06M | ---- | -46.77%26.45M | ---- | -55.22%49.69M | ---- | --110.96M | ---- | ---- |
Special items | ---- | -68.86%20.28M | ---- | 3,330.46%65.13M | ---- | -132.91%-2.02M | ---- | 27.90%6.13M | ---- | 61.41%4.79M |
Operating profit before the change of operating capital | ---- | -39.42%82.07M | ---- | 3,897.49%135.48M | ---- | 101.57%3.39M | ---- | 3.31%-215.61M | ---- | -284.03%-222.98M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | ---- | -82.78%13.1M | ---- | 15.76%76.06M | ---- | 205.89%65.71M | ---- | -620.19%-62.05M | ---- | -83.80%11.93M |
Accounts receivable (increase)decrease | ---- | 233.39%149.68M | ---- | 134.56%44.9M | ---- | -280.54%-129.9M | ---- | -106.92%-34.14M | ---- | -127.34%-16.5M |
Accounts payable increase (decrease) | ---- | 85.21%-12.96M | ---- | 54.37%-87.65M | ---- | -186.21%-192.09M | ---- | 418.89%222.81M | ---- | -95.41%-69.87M |
Cash from business operations | ---- | 37.39%231.89M | ---- | 166.74%168.79M | ---- | -184.18%-252.89M | ---- | 70.08%-88.99M | ---- | -840.36%-297.42M |
Other taxs | ---- | -1,107.64%-5.06M | ---- | 98.57%-419K | ---- | -259.85%-29.23M | ---- | 70.87%-8.12M | ---- | -110.32%-27.89M |
Special items of business | -44.85%109.74M | ---- | 91.24%198.98M | ---- | 157.65%104.05M | ---- | -232.49%-180.48M | ---- | 150.24%136.22M | ---- |
Net cash from operations | -44.85%109.74M | 34.72%226.83M | 91.24%198.98M | 159.68%168.37M | 157.65%104.05M | -190.51%-282.12M | -232.49%-180.48M | 70.15%-97.11M | 150.24%136.22M | -1,308.73%-325.31M |
Cash flow from investment activities | ||||||||||
Interest received - investment | 1,092.96%10.34M | 425.57%3.47M | --867K | -55.79%661K | ---- | 33.60%1.5M | ---- | -1.76%1.12M | ---- | 554.60%1.14M |
Decrease in deposits (increase) | --21.95M | 20.24%-27.65M | ---- | -43.21%-34.66M | ---- | -152.17%-24.2M | ---- | 203.50%46.39M | ---- | ---44.82M |
Sale of fixed assets | -93.89%349K | 65.74%7.56M | --5.71M | -74.76%4.56M | ---- | -71.58%18.06M | ---- | 3,192.75%63.55M | ---- | -75.84%1.93M |
Purchase of fixed assets | 78.69%-1.49M | 80.18%-3.87M | ---6.99M | 80.43%-19.52M | ---- | -239.52%-99.73M | ---- | 82.20%-29.37M | ---- | -128.97%-165.07M |
Selling intangible assets | ---- | --1.33M | ---- | ---- | ---- | --1.86B | ---- | ---- | ---- | ---- |
Purchase of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---53.59M | ---- | ---- |
Sale of subsidiaries | ---- | --30.26M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Recovery of cash from investments | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --13.21M | ---- | ---- |
Other items in the investment business | ---- | ---- | ---- | ---- | -100.36%-6.31M | ---- | 2,828.13%1.74B | 89.25%-645K | 16.23%-63.85M | -143.70%-6M |
Net cash from investment operations | 7,588.70%31.15M | 122.68%11.11M | 93.41%-416K | -102.79%-48.96M | -100.36%-6.31M | 4,208.98%1.75B | 2,828.13%1.74B | 119.10%40.66M | 16.23%-63.85M | -366.63%-212.82M |
Net cash before financing | -29.04%140.9M | 99.26%237.93M | 103.16%198.57M | -91.88%119.41M | -93.74%97.74M | 2,703.65%1.47B | 2,057.78%1.56B | 89.51%-56.45M | 120.83%72.37M | -2,778.44%-538.13M |
Cash flow from financing activities | ||||||||||
New borrowing | 67.40%197.43M | -82.40%129.08M | --117.94M | 42.78%733.52M | ---- | 29.03%513.75M | ---- | -64.21%398.16M | ---- | 60.45%1.11B |
Refund | 21.09%-133.99M | 75.79%-190.8M | ---169.81M | 58.40%-787.98M | ---- | -777.36%-1.89B | ---- | 52.20%-215.91M | ---- | 26.49%-451.74M |
Interest paid - financing | 29.11%-5.74M | 50.62%-13.06M | ---8.09M | 46.77%-26.45M | ---- | 51.52%-49.69M | ---- | 8.91%-102.5M | ---- | -75.36%-112.53M |
Other items of the financing business | ---- | ---- | ---- | ---- | 100.30%4.17M | ---- | -1,841.01%-1.38B | ---- | -117.32%-71.11M | ---- |
Net cash from financing operations | 190.30%56.51M | 13.46%-80.15M | -1,600.91%-62.59M | 93.58%-92.63M | 100.30%4.17M | -2,245.14%-1.44B | -1,841.01%-1.38B | -87.43%67.27M | -117.32%-71.11M | 3,403.25%535.12M |
Effect of rate | 75.78%-2.84M | 32.54%-5.2M | 49.72%-11.71M | -907.75%-7.71M | -4,813.50%-23.29M | 7,246.15%955K | 78.34%-474K | 100.34%13K | -164.89%-2.19M | -1,835.20%-3.79M |
Net Cash | 45.18%197.41M | 489.16%157.78M | 33.43%135.98M | -0.43%26.78M | -43.77%101.91M | 148.73%26.9M | 14,340.64%181.23M | 459.95%10.81M | -98.01%1.26M | 12.16%-3M |
Begining period cash | 207.12%226.24M | 34.92%73.67M | 34.92%73.67M | 104.12%54.6M | 104.12%54.6M | 67.99%26.75M | 67.99%26.75M | -29.92%15.92M | -29.92%15.92M | -13.73%22.72M |
Cash at the end | 112.60%420.81M | 207.12%226.24M | 48.58%197.93M | 34.92%73.67M | -35.80%133.22M | 104.12%54.6M | 1,284.29%207.51M | 67.99%26.75M | -82.37%14.99M | -29.92%15.92M |
Cash balance analysis | ||||||||||
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | -- |
Auditor | -- | Hong Kong Lixin Dehao Certified Public Accountants Limited | -- | Hong Kong Lixin Dehao Certified Public Accountants Limited | -- | Hong Kong Lixin Dehao Certified Public Accountants Limited | -- | Hong Kong Lixin Dehao Certified Public Accountants Limited | -- | Hong Kong Lixin Dehao Certified Public Accountants Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.